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Abstract A new chromatographic method for the
enantioseparation and the determination of (−)-trans-paroxe-
tine and (+)-trans-paroxetine has been developed with the aid
of amylose ovomucoid-based chiral stationary phase. The
method is faster and five times more sensitive than proce-
dures recommended previously: limit of detection and limit of
quantification are 5 and 16 ng/mL, respectively [modified
(Ferretti et al. in J Chromatogr B 710:157–164, 1998): 20
and 60 ng/mL]. It was carefully validated and applied for the
determination of (−)-trans-paroxetine and (+)-trans-paroxe-
tine in Parogen (Mc Dermott Laboratories Ltd.) and Xetanor
(Actavis) coated tablets.
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Introduction
In case of chiral drugs, substantial differences in transport,
distribution, metabolism, and excretion of particular enantio-
mers may be observed. Hence, for medicinal products
marketed as formulations containing only one enantiomer, a
very important issue is the content of the second enantiomer,
which in the best case may appear as an inactive impurity but
may also be responsible for undesired effects. The most
popular techniques used for drugs enantiomeric purity
estimation are high-performance liquid chromatography
(HPLC) [1–3] and capillary electrophoresis [4, 5], enabling
both enantiodifferentiation and enantiomers quantification.
Paroxetine ((−)-trans-paroxetine: (3S-trans)-(−)-(3S,4R)-
4-(4-fluorophenyl)-3-[[(3,4-methylenedioxy)phenoxy]-
methyl]piperidine) is a compound belonging to selective se-
rotonin reuptake inhibitors, drugs used in major depression
[6], obsessive-compulsive, as well as generalized and social
anxiety disorders [3]. With the exception of a low affinity to
muscarinic receptors, which is not relevant for therapeutic
effects, it does not interact directly with monoamine neuro-
transmitter receptors [7]. Paroxetine, containing two chiral
carbon centers may form four optical isomers—two for cis-
and two for trans-paroxetine. In therapeutics, it is used as (−)-
trans-paroxetine. In pharmaceutical formulations, its most
likely not active enantiomer, (+)-trans-paroxetine, may also
be present [2].
For the determination of paroxetine enantiomers, few
HPLC stationary phases (including optically active metal
complexes, cyclodextrin, penicillamine, and Pirkle type com-
p lexes ) [3 , 8 ] were examined , bu t reasonab le
enantioseparation was obtained only with the aid of amylose
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[3, 9, 10]- and cellulose [3]-based chiral stationary phases.
Carboxymethyl-β-cyclodextrin was also recommended asmo-
bile phase modifier improving efficiency of the process [11].
In the present paper, we describe new high-performance
liquid chromatographic method for paroxetine enantiomers
separation and determination with use of silica-based chiral
stationary phase containing glycoprotein (ovomucoid [12, 13])
as chiral selector, more sensitive and offering better resolution
than those recommended before. The method was validated
and applied to paroxetine enantiomers quantification in two
pharmaceutical formulations: ParoGen (Mc Dermott
Laboratories Ltd.)- and Xetanor (Actavis)-coated tablets con-
taining 20 mg paroxetine (as paroxetine hydrochloride,
22.22 mg). Validated HPLC method with amylose tris(3,5-
dimethylphenylcarbamate) chiral stationary phase was used a
reference procedure. It should be noted that the present method
was developed as a result of extensive studies with such chiral
selectors as hydrocarbons (cellulose and amylose), proteins,
and cyklodextins. More than 20 aqueous and non-aqueous
mobile phases were examined.
Materials and methods
Medicinal products
ParoGen-coated tablets, 20 mg paroxetine as paroxetine
hydrochloride (22.22 mg; McDermott Laboratories Ltd.);
Xetanor-coated tablets, 20 mg paroxetine as paroxetine
hydrochloride (22.22 mg; Actavis).
Reference substances (standards)
Paroxetine hydrochloride (anhydrous) ((−)-trans-paroxetine
hydrochloride) 96.2 % (Matrix Laboratories Ltd., WS batch
number QC-3/PRH/WS001/008), quality assurance laborato-
ry label 678a/PS/J; (+)-trans-Paroxetine hydrochloride (hemi-
hydrate; Gedeon Richter Ltd. batch number R4B0310), qual-
ity assurance laboratory label 97a/PS/J; (+)-trans-Paroxetine
hydrochloride (USP Paroxetine Related Compound C) 99.9%
(Sumika batch number STS-01), quality assurance laboratory
label 97/PS/J.
Placebo of medicinal product ParoGen-coated tablets
(Alphapharm batch number P576), quality assurance labora-
tory label 687a/PS/J; placebo of medicinal product Xetanor,
prepared according to manufacturer recipe.
Reagents
n-Hexane 95 % and acetonitryle HPLC (Labscan Ltd.), etha-
nol and methanol HPLC (Merck), ethanolamine (2-
aminoethanol reagent plus ≥99 %; Sigma-Aldrich), potassium
phosphate, phosphoric acid, potassium hydroxide (POCh).
Apparatus
Chromatographic set-up Dionex Ultimate 3000 LC composed
of LC pump, UV-VIS detector, autosampler, thermostat, and
Chromeleon software. Chiral separations were performed
using:
( a ) ovomucoid (g lycopro te in) immobi l ized on
aminopropylsilane-derivatized silica (Ultron ES-OVM
150×4.6 mm, 5 μm, Agilent Technologies) column-
mobile phase: 10 mM phosphate buffer pH 3.5 (1.36 g
K2HPO4/1,000 ml water, pH adjusted to 3.5 with
H3PO4conc. or 1 M KOH)-acetonitrile (98:2, v/v), detec-
tion UV (295 nm, t=23 °C), flow rate (1.5 mL/min). For
the preparation of calibration curves, methanol-pH 3.5
phosphate buffer solutions containing 0.01 to 100μg/mL
of the analyte were applied (injection volumes, 20 μL)
(b) silica based amylose tris(3,5-dimethylphenyl)carbamate
(Chiralpak AD-H 250×4.6 mm, 5 μm, Daicel Chemical
Industries Ltd.) column (modified procedure described
elsewhere [9])-mobile phase: hexane-ethanol-
ethanolamine (80:20:0.2, v/v/v), flow rate (1.0 mL/min),
detector UV (295 nm, t=23 °C). For the preparation of
calibration curves, methanol-ethanol solutions contain-
ing 0.01 to 100 μg/mL of the analyte were applied
(injection volumes, 20 μL).
Methods
Analysis of medicinal preparations ParoGen 20 mg-coated
tablets and Xetanor 20 mg-coated tablets
Paroxetine standard solution preparation: 2 mg of (−)-trans-
paroxetine standard was weighed and transferred into 100 mL
volumetric flask. Then, 10 mL of methanol was added and the
flask was filled with: ethanol for the analysis with use
Chiralpak AD-H column, 10 mM pH 3.5 phosphate buffer
for the analysis with use of Ultron ES-OVM column.
Placebo extract preparation: accurate weight amount of
placebo corresponding to excipients content in a tablet
(280 mg) was placed into 100 mL volumetric flask and
10 mL methanol was added. The sample was sonicated
for ∼10 min. The volumetric flask was filled with methanol
and the resulted suspension was filtered. 5.0 mL of the filtrate
was placed into 50 mL volumetric flask and filled with ap-
propriate solvent or solution (depending on the column used,
see above).
Extraction of paroxetine from ParGen and Xetanor phar-
maceutical formulations: tablets of the formulations were
carefully ground. Accurate weight amount of each preparation
corresponding to one dose (300 mg) was placed into 100 mL
volumetric flask and extracts were prepared as described in
above para.
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Determination of analyte recovery within the content range
of 80–120 % (according to ICH Validation of Analytical
Procedures [14]): accurate weight amounts of placebo corre-
sponding to excipients contained in one tablet (280 mg) were
transferred into nine volumetric flasks (100 mL). Accurately
weighed amounts of (−)-trans-paroxetine hydrochloride were
poured into each flask: ca. 16 mg (80 % dose) to first three
flasks, ca. 20 mg (100 % dose) to subsequent three flasks and
ca. 24 mg (120 % dose) into the last three flasks. Ten milliliter
methanol was added to each flask. The flasks were sonicated
for ∼10min, filled with methanol and the resulted suspensions
were filtered. Of each filtrate, 5.0 mL was placed into 50 mL
volumetric flask and filled with ethanol (Chiralpak) or phos-
phate buffer (Ultron).
Results and discussion
Robustness of the method
Influence of mobile phase composition and flow rate as well as
column temperature on the precision of retention times and
peak areas measurements and selectivity was examined.
Twenty-microliter portions of (−)-trans-paroxetine hydrochlo-
ride standard solution (in phosphate buffer) were injected onto
a column and chromatograms were registered (n=6 for each
measurement). Precision of retention times (tR), peak areas
measurements and resolution (Rs) were calculated. The obtain-
ed results prove good repeatability of the developed method
with relative standard deviation (RSD) for retention times and
peak areas between 0.11 and 3.09 %. It was also found, that
changing acetonitrile content (±0.2 %), column temperature
(±3 °C) and flow rate (±0.5 mL/min) did not much influence
resolution factor (|ΔRs|<0.3) although with the flow rate eleva-
tion decrease in the resolution factor could be observed (Fig. 1).
For the estimation of intraday precision (repeatability) of the
method, eight 20-μL portions of the (−)-trans-paroxetine hy-
drochloride standard solution were injected onto columnwithin
the same day in six series. Precision of measurements of peak
area (RSD=0.29 %; confidence level, p<0.05; confidence
interval, Δx=±0.26 %) and of retention time (RSD=0.53 %,
p<0.05,Δx=±0.015 min) were determined. Interday precision
(intermediate precision) was evaluated, as well. Of the samples,
20 μL of the analyte were examined within three consecutive
days (n=3 for each day). It was found that RSD of the peak area
measurements was=0.43 % (p<0.05, Δx=±0.33 %) and of
retention time 4.86 %, p<0.05, Δx=±0.124 min.
Stability of the solution of (−)-trans-paroxetine hydrochlo-
ride was examined within seven consecutive days (0, 24, 48,
and 168 h, n=2 for each sampling time). RSD of the results of
peak area and retention timemeasurements, respectively, were
calculated: 0.48 %, p<0.05,Δx=±0.41 % and 9.2 %, p<0.05,
Δx=±0.253 min.
Comparative study concerning the developed method
and already published one [9]
Both methods for the separation and determination of (−)- and
(+)-trans-paroxetine were carefully validated. With use of
ovomucoid stationary phase resolution (Rs) was 2.60 (mobile
phase, 10 mM phosphate buffer pH 3.5-acetonitrile 98:2, v/v,
t=23 °C, flow rate 1.5 mL/min)1 and on tris(3,5-
dimethylphenyl)carbamate stationary phase-1.5 (mobile
phase, hexane-ethanol-ethanolamine (80:20:0.2, v/v/v); flow
rate, 1.0 mL/min; t=23 °C; this result was not in agreement
with previously reported [9], where Rs=2.78 was claimed, but
in the present study modified mobile phase was used). The
elution order of the enatiomers was (−)- before (+)-enantiomer
1 Rs=2.82 for flow rate 1.0 mL/min.
Fig. 1 Influence of flow rate (a),
acetonitrile content (b), and
temperature (c) on the resolution
of (±)-paroxetine on ovomucoid
stationary phase
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Fig. 3 Chromatograms of
ParoGen 20 mg coated tablets on
a silica-bound ovomucoid (Ultron
ES-OVM 150×4.6 mm, 5 μm;
mobile phase: 10 mM phosphate
buffer pH 3.5-acetonitrile 98:2,
v/v, t=23 °C, flow rate 1.5
mL/min) and b amylose tris
(3,5-dimethylphenyl)carbamate
(Chiralpak AD-H 250×4.6 mm,
5 μm; mobile phase: hexane-
ethanol-ethanolamine 80:20:0.2,
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Fig. 2 Chromatograms
representing: a LOQ for (−)- and
(+)-paroxetine enantiomers and b




150×4.6 mm, 5 μm) stationary
phase; mobile phase: 10 mM
phosphate buffer pH 3.5-
acetonitrile 98:2, v/v, t=23 °C,
flow rate 1.5 mL/min
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on ovomucoid, but (+)- before (−)-enantiomer on amylose
tris(3,5-dimethylphenyl) carbamate stationary phase
(Electronic supplementary material (ESM) Fig. S1). Both
(−)- and (+)-trans-paroxetine exhibited linear response in the
range of 0.01 to 100 μg/ml (R2≥0.998).
Both limit of detection, LOD, and limit of quantification,
LOQ (estimated as the amounts for which signal-to-noise ratios
were S/N>3 and>10, respectively), were significantly lower
on ovomucoid (LOD 0.005 and 0.006 μg/mL and LOQ 0.016
and 0.020 μg/mL for (−)- and (+)-paroxetine, respectively;
Fig. 2a) than on amylose tris(3,5-dimethylphenyl)carbamate
stationary phase (LOD (0.020 μg/mL) and LOQ (0.060 μg/
mL) for (−)- and (+)-paroxetine). Even 0.01 % of (+)-paroxe-
tine can be detected in the presence of (−)-paroxetine on
ovoomucoid stationary phase (Fig. 2b). Absence of excipients
peaks within analytical retention times proves good selectivity
of the developed procedure.
Determination of (−)-trans-paroxetine in medicinal products
(ParoGen- and Xetanor-coated tablets)
(−)-trans-Paroxetine contents were determined in ParoGen-
and Xetanor-coated tablets with the aid of ovomucoid as well
as amylose carbamate stationary phases (Fig. 3, Table 1).
They were found to be between 21.13 and 22.27 mg, with
RSD between 0.67 and 1.14 %. Recovery of the analyte was
in the range of 98.35–101.87 %. Thanks to suitably low LOQ
(16 ng/ml), the method possibly could be recommended for
the determination of paroxetine enantiomers in body fluids.
Purity of the examined formulations was also checked.
According to European Pharmacopeia 7.7 monograph for
active substance “Paroxetine hydrochloride anhydrous”, an
amount of D contamination, (+)-trans-paroxetine hydrochlo-
ride, should not exceed 0.2 % with respect to (−)-trans-parox-
etine hydrochloride. In the examined tablets, no (+)-trans-
paroxetine enantiomer in the amount ≥0.01 % was found
under available analysis conditions.
Conclusion
New chromatographic method for the enantiodifferentiation
of (±)-trans-paroxetine and the determination of (−)- and (+)-
trans-paroxetine contents was developed with the aid of
ovomucoid stationary phase. The new method is selective,
precise, accurate, and offers good recovery (>98 %).
Resolution, Rs=2.8 is similar to the previously reported [10],
2.78. However, it is faster and few times more sensitive (LOD
and LOQ, 5 and 16 ng/mL, respectively, comparing to 20 and
60 ng/mL, obtained for modified procedure [9]). The obtained
results (elution order) shows that (+)-trans-paroxetine (as
compared to (−)-enantiomer) forms more stable solute-
stationary phase complex on ovomucoid than on amylose
tris(3,5-dimethylphenyl)carbamate stationary phase. The de-
veloped method allows for the determination of active sub-
stance paroxetine hydrochloride in bulk and in pharmaceutical
formulations according to European Pharmacopeia 7.7 re-
quirements [14]. In the examined pharmaceutical formula-
tions, ParoGen- and Xetanor-coated tablets, no (+)-trans-par-
oxetine enantiomer in the amount ≥0.01 % was found under
analysis conditions.
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